Bruker Corporation (BRKR)vsDexCom Inc (DXCM)
BRKR
Bruker Corporation
$61.21
-0.60%
HEALTHCARE · Cap: $9.35B
DXCM
DexCom Inc
$89.17
-0.20%
HEALTHCARE · Cap: $33.72B
Smart Verdict
WallStSmart Research — data-driven comparison
DexCom Inc generates 42% more annual revenue ($4.97B vs $3.50B). DXCM leads profitability with a 20.1% profit margin vs -2.0%. DXCM appears more attractively valued with a PEG of 1.37. DXCM earns a higher WallStSmart Score of 74/100 (B).
BRKR
Hold37
out of 100
Grade: F
DXCM
Strong Buy74
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+6.2%
Fair Value
$45.25
Current Price
$61.21
$15.96 discount
Intrinsic value data unavailable for DXCM.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Every $100 of equity generates 38 in profit
Keeps 20 of every $100 in revenue as profit
Strong operational efficiency at 24.3%
Earnings expanding 43.6% YoY
Areas to Watch
Expensive relative to growth rate
Distress zone — elevated risk
Weak financial health signals
ROE of -0.5% — below average capital efficiency
Premium valuation, high expectations priced in
Trading at 12.8x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : BRKR
BRKR has a balanced fundamental profile.
Bull Case : DXCM
The strongest argument for DXCM centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 20.1% and operating margin at 24.3%. Revenue growth of 13.1% demonstrates continued momentum.
Bear Case : BRKR
The primary concerns for BRKR are PEG Ratio, Altman Z-Score, Piotroski F-Score.
Bear Case : DXCM
The primary concerns for DXCM are P/E Ratio, Price/Book.
Key Dynamics to Monitor
BRKR profiles as a turnaround stock while DXCM is a mature play — different risk/reward profiles.
DXCM carries more volatility with a beta of 1.42 — expect wider price swings.
DXCM is growing revenue faster at 13.1% — sustainability is the question.
DXCM generates stronger free cash flow (185M), providing more financial flexibility.
Bottom Line
DXCM scores higher overall (74/100 vs 37/100), backed by strong 20.1% margins and 13.1% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Bruker Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Bruker Corporation develops, manufactures and distributes scientific instruments and analytical and diagnostic solutions in the United States, Europe, Asia Pacific, and internationally. The company is headquartered in Billerica, Massachusetts.
Visit Website →DexCom Inc
HEALTHCARE · MEDICAL DEVICES · USA
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?